Document Detail

Validity of plasma fibrinogen, D-dimer, and the von Willebrand factor as markers of cardiovascular morbidity in patients on chronic hemodialysis.
MedLine Citation:
PMID:  16449948     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Among the non-classic cardiovascular disease risk factors in end-stage renal disease patients on chronic hemodialysis (HD), plasma fibrinogen, D-dimer, and von Willebrand factor (vWf) levels are potential markers of cardiovascular morbidity. We designed this case-control study to investigate their validity and any differences between them. MATERIAL/METHODS: Twenty-five HD patients (18 males, mean age: 63, range: 52-69 years) comprised the group with prevalent cardiovascular disease (CVD) and 50 HD patients (35 males, mean age: 62, range: 40-77 years) with non-evident cardiovascular disease history constituted the second study group. Twenty-five healthy non-smoking volunteers served as controls for comparison with the study groups. RESULTS: Patients with CVD had significantly higher concentrations of plasma fibrinogen, D-dimer, and vWf than patients without incident CVD. All three parameters correlated positively with cardiovascular morbidity, i.e. fibrinogen (r=0.378, P<0.001), logDD (r=0.70, P<0.001), vWf (r=0.214, P<0.001), and logCRP (r=0.704, P<0.001). Among them, D-dimer exhibited the characteristics most coherent with CVD. The age- and sex-adjusted odds ratio (OR) of D-dimer for the presence of CVD was 2.0, which did not change appreciably when adjustments for several pathophysiological clusters of variables were made, except for a marginal reduction in OR following adjustment for markers of inflammation. CONCLUSIONS: Among the coagulation molecules studied, plasma D-dimer levels exhibited the characteristics most coherent with associated CVD and were found to be strongly and independently associated with the prevalence of CVD in HD patients.
Dimitrios Kirmizis; Apostolos Tsiandoulas; Maria Pangalou; Evangelia Koutoupa; Paraskevi Rozi; Maria Protopappa; Konstantinos Barboutis
Related Documents :
18079478 - A419c (e111a) polymorphism of the glyoxalase i gene and vascular complications in chron...
1928078 - Erythropoietin use in peritoneal dialysis patients.
17452088 - Migrating and herniating hydatid cysts.
17220638 - Phosphate salivary secretion in hemodialysis patients: implications for the treatment o...
19880688 - Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 pati...
24660538 - The activity of 8-iso-prostaglandin f2alpha as an oxidative stress marker in vivo in pa...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2006-01-26
Journal Detail:
Title:  Medical science monitor : international medical journal of experimental and clinical research     Volume:  12     ISSN:  1234-1010     ISO Abbreviation:  Med. Sci. Monit.     Publication Date:  2006 Feb 
Date Detail:
Created Date:  2006-02-20     Completed Date:  2006-04-10     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9609063     Medline TA:  Med Sci Monit     Country:  Poland    
Other Details:
Languages:  eng     Pagination:  CR55-62     Citation Subset:  IM    
Department of Nephrology, Serres General Hospital, Serres, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biological Markers / blood
Cardiovascular Diseases / blood*,  etiology
Case-Control Studies
Fibrin Fibrinogen Degradation Products / metabolism*
Fibrinogen / metabolism*
Kidney Failure, Chronic / blood,  complications,  therapy
Middle Aged
Odds Ratio
Renal Dialysis*
Reproducibility of Results
von Willebrand Factor / metabolism*
Reg. No./Substance:
0/Biological Markers; 0/Fibrin Fibrinogen Degradation Products; 0/fibrin fragment D; 0/von Willebrand Factor; 9001-32-5/Fibrinogen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Health problems among six-week old Pacific infants living in New Zealand.
Next Document:  Establishing melanocyte cultures in a serum-free system for transplantation in vitiligo patients.